Sufentanil Intranasal

Summary

Study of the effects of intranasal sufentanil on patients presenting to the emergency department with acute post-traumatic pain.

Timeline

Start

2020-01-22

Primary completion

2025-07-30

Completion

2025-09-01

Outcome

Met primary endpoint

paper The intranasal sufentanil group (83 patients) showed a significantly greater reduction in pain PMID 37770120 ↗

paper reduction in VAS score 3.0 (IQR 1.7-5.0) vs 1.5 (IQR 0.9-3.0); p<0.001 PMID 37770120 ↗

Publications

• Malinverni S, Kreps B, Lucaccioni T, Bouazza FZ, Bartiaux M, Plumacker A, Pascu A, Youatou Towo P. Effect of intranasal sufentanil on acute post-traumatic pain in the emergency department: a randomised controlled trial. Emerg Med J. 2024 Jan 22;41(2):83-88. doi: 10.1136/emermed-2023-213353.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sufentanil	Other / unclassified	0.3 ug/kg	Intranasal

Indications

No indication recorded.